Institute for Radiation Sciences
Laboratory for Radiation Chemical Biology
Research Interests
- Drug development for Targeted Alpha Therapy (TAT)
- Functional analysis of lipids-related molecules involved in innate immunity
- Investigation of intermolecular interactions by glycans
- Analysis of molecular dynamics using live cell imaging
Targeted Alpha Therapy (TAT) is a drug therapy that delivers high-energy α-emitting radionuclides to cancer cells to kill them, and is attracting attention as a novel treatment for refractory cancer. We have developed a drug candidate compound labeled with astatine 211 (211At), a short-lived α-emitting radionuclides, and are conducting research in preparation for the First-in-Human (FIH) study, the first clinical trial in which the compound will be administered to humans.
In collaboration with synthetic organic chemists, we are also developing fluorescently labeled bioactive molecules and analyzing the functions of sugar- and lipid-related molecules involved in pathological conditions, such as infectious diseases, cancer, and diabetes from a molecular chemistry perspective.
